Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211664 | 1.00 | ESR1 (0.63) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL2246272 | 0.93 | ESR1 (0.71) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL31356495 | 0.93 | ESR1 (0.71) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL21612683 | 0.91 | ESR1 (0.69) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL12521562 | 0.87 | LMNA (0.47) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL1107365 | 0.85 | ESR1 (0.60) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL22031202 | 0.82 | LMNA (0.53) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| SCHEMBL22035223 | 0.82 | LMNA (0.55) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| Hexestrol SCHEMBL27352072 | 0.82 | ESR1 (0.79) | ESR1LMNACYP3A4MAPTCYP2C9 | |
| 4-Acetoxyphenol SCHEMBL203149 | 0.82 | LMNA (0.67) | ESR1LMNACYP3A4MAPTSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-20210015752-A1 | METHODS FOR PRODUCING PARTICLES OF AN ACTIVE INGREDIENT | SAVIOR LIFETEC CORPORATION (TW) | 2021-01-21 | — | — | US | disclosed |
| CN-111093632-A | Method for producing active ingredient particles | 展旺生命科技股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3638212-A2 | METHODS FOR PRODUCING PARTICLES OF AN ACTIVE INGREDIENT | Savior Lifetec Corporation (TW) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232053-A2 | METHODS FOR PRODUCING PARTICLES OF AN ACTIVE INGREDIENT | SAVIOR LIFETEC CORPORATION (TW) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018136909-A1 | PREPARATION OF MICROPARTICLES OF AN ACTIVE INGREDIENT | SAVIOR LIFETEC CORPORATION (TW) | 2018-07-26 | — | — | WO | disclosed |
| EP-1765295-B1 | SUSTAINED-RELEASE COMPOSITION, PROCESS FOR PRODUCING THE SAME AND USE OF THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8088726-B2 | Mixing an aqueous solution of a drug (LH-RH derivative) and an acid or base in a molar amount of about 1.5 or more times that of the drug with a solution of a biodegradable polymer, and drying the mixture; stable water in oil emulsion; reduced drug leakage during production; high drug content | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-5100669-A | Controlled release drug delivery | BIOMATERIALS UNIVERSE, INC. (JP) | 1992-03-31 | — | — | US | disclosed |
| US-5061492-A | biodegeadeable polymer matrix is copolymer of gylcolic acid a nd lactic acid | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| US-4917893-A | Prolonged release microcapsules | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0330180-A1 | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same | Biomaterials Universe, Inc. (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0145240-B1 | METHOD FOR PRODUCING MICROCAPSULE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | disclosed |
| US-4652441-A | WATER SOLUBLE DRUGS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
| EP-0145240-A2 | Method for producing Microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | ESR1 3737/4885LMNA 262/4885CYP3A4 3356/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | ESR1 3737/4885LMNA 262/4885CYP3A4 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.